Back to search results

Study of RAS(ON) Inhibitors for Advanced RAS-mutated NSCLC

This study is testing new treatments called RMC-6291 and RMC-6236, alone or with standard treatments like Pembrolizumab, Cisplatin, or Carboplatin. These treatments are for people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that have specific changes in the RAS gene (like KRAS, NRAS, HRAS, or KRAS G12C). The main goals are to see how safe these new treatments are and if they cause any serious side effects. We also want to see if they help shrink tumors. You may be able to join if you are 18 or older, have good organ function, and have already received standard treatments for your cancer. The study is currently unclear on its recruitment status and plans to enroll about 616 people.

Study design
This is an open-label platform study, meaning you and your doctors will know which treatment you are receiving. It is a Phase 1b/2 study, which means it's looking at safety and early signs of effectiveness.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for adverse events (side effects) for up to 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Recruiting
PHASE1Ages 18+InterventionalTreatment
Revolution Medicines, Inc.
~616 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:RMC-6291RMC-6236PembrolizumabCisplatinCarboplatinPemetrexed

At a glance

Recruiting sites
93 of 93 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events
Measured over Up to 5 years
+1 more outcome measured

Conditions

Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC

Explore related trials

Lung Non-Small Cell CarcinomaSolid NeoplasmGTPase KRasRAS Family Oncogene

NCT06162221

Where you'd take part

This study runs at 93 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italystudy coordinator listed

    Recruiting

  • Boca Raton Clinical Research Associates

    Plantation, Floridastudy coordinator listed

    Recruiting

  • Cancer Specialists of North Florida

    Saint Augustine, Floridastudy coordinator listed

    Recruiting

  • Centre François Baclesse

    Caen, Francestudy coordinator listed

    Recruiting

  • Centre Georges François Leclerc

    Dijon, Bourgogne-Franche-Comté, Francestudy coordinator listed

    Recruiting

  • Charite-Universitaetsmedizin Berlin - Campus Charite Mitte

    Berlin, Germanystudy coordinator listed

    Recruiting

  • CHU de Lille Institut Cœur Poumon

    Lille, Hauts-de-France, Francestudy coordinator listed

    Recruiting

  • CHU de Nantes

    Nantes, Hauts-de-France, Francestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Revolution Medicines · STUDY_DIRECTOR · Revolution Medicines

Who to contact

Revolution Medicines
[email protected]
1-844-2-REVMED
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥ 18 years of age
ECOG PS is 0 to 1
Adequate organ function as outlined by the study
Received prior standard therapy appropriate for tumor type and stage
Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Exclusion

Primary central nervous system (CNS) tumors
Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
Major surgery \< 28 days of first dose
Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids

What this trial measures

  • Adverse eventsUp to 5 years

    Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs

  • Dose limiting toxicities21 days

    Number of participants with dose limiting toxicities